Lymphocytes isolated from the blood of patients and healthy donors include a population of cells that destroy target cells in the direct cell-mediated cytotoxic assay with little indication of specificity. This natural reaction is the dominant feature of most cell-mediated cytotoxic tests and, although it appears to be mostly nonselective, it possesses some selective activity. The observed cytotoxicity from these reactions depends mostly on the reactivity of the effectar cell; when several effector cells are tested on differ ent target cells, the relative order of acti@tityis usually main tamed on the different target cells. When this natural cyto toxicity was analyzed without regard to the type of cancer of the patient or of the target cells, a weak decline in the average reactivity was observed with increasing tumor in valvement.
possessed Fc receptors, was responsible for the effect. Lymphocyte suspensions isolated from different persons vary considerably in N-cell activity so that when many pen sons are tested a wide range of cytotoxicity is observed.
Past attempts to monitor patients for CMC2 or to relate CMC and the staging of cancer dealt with specific cytatoxic ity for the type of cancer (3, 6, 20, 22) . The inadequacies of the method used for demonstrating specificities in these studies have been thoroughly discussed (1, iO, 18) , as have been the difficulties involved in monitoring patients (7) for specific immunity. However, several of these studies me ported a decline in specific CMC with advancing disease (3, 6) . The results from the present study, which tested patients without regard to the type of cancer, suggest that the de dine iS nonselective on due to an effect on natural cytotox icity.
MATERIALS AND METHODS

Patients and Controls. Classification of patients was es
sentiably through the TNM system with updating by the attending physician through clinical and laboratory studies. Since the composition of the stages varies with the site of the tumor and a wide variety of cancers was tested, the reader should refer to the TNM system proposed by Union International Contra Cancer (23, 29) for grouping patients into stages. The tests were performed with cells from pa tients in the UCLA Hospital presenting tumors except those patients who had just undergone surgery. A total of 239 patients were tested in this series: melanoma, 38; bladder, 39; breast, 21; prostate, 19; cervix, 17; gastrointestinal, 13; lung, 8; larynx, 8; ovarian, 7; vaginal, 7 ; and a variety of other cancers, 62. From these patients 227 were classified into 4 stages as follows: Stage 1,41; Stage 11,68; Stage 111,32; and Stage IV,86. Concurrently, 224 individuals without can cer were also tested ; 123 of these had a close association with our laboratory.
Patients were also classified according to the treatments they had received. These groups included 25 untreated patients, 122 patients who had undergone surgery, 6 treated with radiation, 8 treated with drugs, and 72 treated with combinations of such therapies in their histories. Of these, 33 had surgery and radiation, 30 had surgery and chemotherapy, 1 had radiation and drugs, and 8 had all 3 forms of treatment. The patients were divided into groups When a patient with a specific type of cancer reacts selectively against a target cell derived from the same can cer, the reaction is often said to be disease rebated or tumor associated. This is often supported by findings reporting a higher proportion of patients reacting selectively against the target cell in comparison with control individuals. How ever, many specificities can be involved in selective reac tians between effector and target cells so that the relation ship of cytotoxicity to disease or cancer cannot be under stood without first determining the exact specificity with which we are concerned . Only after the specificity is identi fied and its relationship to disease is determined can we discuss tumor-associated reactivity. With our present state of knowledge, it is not possible to predict or diagnose the type of cancer from the pattern of reactions observed.
The dominant aspect of most direct cell-mediated cyto toxic test results is natural cytatoxicity exhibited by effector cells from nearly all individuals whether they have cancer or not (13, 27, 28 
@
Significant difterence (P < 0.05)with respect to other noncancer controls (Column 2).
by treatment, retrospectively, as another way of examining the same population of patients. Microassay for Cell-mediated Immunity. All lymphocyte samples were isolated from hepaminized peripheral blood by centnifugation on FicoII-Hypaque and tested as described previously (28) . Target cells used in the study have been described (17, 28) except for Targets 804, 917, 952, 1042, and 1046. Target 804 is a subline of Gi 1, and Target 1046 is a subline of T24, derived from a breast cancer and a bladder cancer, respectively. Targets 952 and 1042 were derived from osteosarcomas and Target 917 is from a melanoma.
RESULTS
We had observed previously that lymphocytes from healthy individuals associated with our laboratory and used as controls in CMC tests reacted more strongly than did other controls without cancer and that, together, they were slightly greater in cytotoxicity than cancer patients. The reactivity was, however, based on average scares with con siderable variability and overlapping so that many patients were stranger reactors than healthy controls were. Table 1 shows a comparison of patients divided into groups by stages with controls consisting of persons associated with our laboratory and others with no indication of cancer. The table also shows results among patients that were signifi cantly different from those of the total control group and the controls after exclusion of results from laboratory person neb. Regardless of the controls used, cancer patients were generally weaker, with more significant differences in the later stages.
In comparison with all noncancer controls, Targets 370, 372, 462, 497, 548, 696, 804, 952, and 1042 showed signifi cant depression in activity at some stage, whereas targets 697, 9i7, and 1046 showed weaken indications without sig nificance. After exclusion of laboratory personnel from the Table 2 control group, significant depression was observed with Targets 372, 497, 548, 696, and 952. Results on Target 9i 7 showed significantly higher activity with patients during Stages I and III, but the control value against this target is suspiciously low.
The especially weak cytotoxicity by Stage IV patients mdi cated a declining reactivity rather than depressed reactivity for all cancer patients. Besides showing the decrease in mean cytotaxicity with progressive stages, we attempted to demonstrate declining reactivity in cancer patients by anal ysis for correlation of cytataxicity with stages (Table 2) . Although significant correlations were achieved with only 2 target cultures, 11 of the 12 target cells showed negative coefficients. The negative slope in Table 2 shows the de dine in cytotoxicity with progressive stages for the best fitting line.
The difficulties of staging cancer became apparent early in the study of tumor involvement and reactivity. The most objective method of staging was the TNM system but its accuracy decreased with the time interval between staging and testing. Updating by clinical criteria was useful but less precise. Although, admittedly, staging is weaker than desin able, we felt that it did reflect increasing tumor involvement which correlated with declining cytotoxicity (Tables 1 and  2) . From a different point of view, patients were divided into groups according to the type of treatment received. The average reactivity for each group is presented in Table 3 . Division according to treatment left the categories of pa tients with radiation only, with chemotherapy only, with radiation and chemotherapy combined, and with all 3 forms of treatment, with insufficient numbers for stable compani sons. Untreated patients were, however, among the stronger reactors against Targets 370, 372, 497, 548, 804, 917, and 1042. Most groups with sufficient numbers were weaker than controls although the differences were not striking. The weakest group in Table 3 consisted of those treated by surgery and chemotherapy, suggesting the pos sible effect of drugs on the cytotoxicity exhibited.
Decline of Cell-mediated Cytotoxicity in Patients
Because immunosuppression during chemotherapy could account for the weak average reactivity of Stage IV patients, we averaged the results for all patients who had received chemotherapy. These patients as a group were less reactive than were controls and mast other patients. However, when patients treated with drugs were excluded in calculating the average for Stage IV patients, the mean scare was still depressed, indicating that factors other than drugs were responsible far the declining reactivity. These results are shown in Table 4 .
Classifying the patient population by staging and by treat ment appear to be different approaches to the problem, but a close relationship exists between the 2 methods (Table 5) . Information on this relationship also supplied a better un derstanding of the patient population tested. Table 5 shows the past treatment of the patients divided by stages. The percentage of untreated cases and those treated by surgery alone decreases with progressive stages, whereas the pen centage of patients treated by radiation and chemotherapy increases. The percentage of patients tested who had un dergone surgery remained rather constant, indicating the nature of the UCLA Hospital as one receiving referrals from the community after primary treatment. Since only patients with tumors were included in the study, the analysis by treatment supported the conclusions drawn from staging. Although we previously examined the relationship be tween age and cytotaxic reactivity on a larger set of healthy individuals (24) and concluded that little or no relationship existed, the barge difference between our laboratory per sonnel and other normal persons and patients persisted. A reasonable explanation was the difference in ages since the median age for our laboratory workers was younger than for other healthy persons who, in turn, were younger than the patients. As found in the studies on mice (9, 14), we ex pected to find a decline with age (Table 6 ). No significant differences were observed an 12 targets when we tested persons without cancer who were divided into 3 age groups. With patients only, a very slight decline in reactivity was observed in tests with those over age 70 (Table 7) . 
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Significant differences were observed on Targets 462, 917, supposedly have not experienced immunological contact and 1042 when the over-70 group was compared to those with the specificities under study. Also, the variability intro under age 29. duced into the test through the preparation of the effecton The results in Tables 6 and 7 were also studied for come-cells, culturing of target cells, or technical aspects of the lations between age and cytatoxicity by regression analysis. test makes it difficult to base conclusions on tests with i or These results are shown in the last mowsfor both tables. The a few patients. The difficulties arise from variability in me only significant decline with age was observed on Target 1042 with cancer patients. If any relationship does exist in Table 5 humans between age and CMC, it is extremely weak. When all tests including patients and controls are combined (me suIts not shown), the decline with age becomes more marked.@However, this decline can be explained by the _______________________________________________ difference in reactivity between our laboratory personnel and patients and is probably less related to age.
DISCUSSION
Several investigators have recently reviewed the difficul ties in detecting specificities through cell-mediated cyto toxic tests and in monitoring the patient during the course of disease (1, 7, 10, 18, 19) . A major problem is the strong natural reactivity exhibited by controls, i.e., persons who 
Decline of Cell-mediated Cytotoxicity in Patients
suits not only from the patients but also from the controls that are used . We attempted to solve these problems by examining more stable patterns of reactivity obtained from testing larger samples. Classification of patients into differ ent categories, however, tended to decrease sample size and the reliability of the results.
Accurate classification of patients with all types of can cers into stages is a formidable problem (23) . Precise stag ing, even when achieved, loses definition with advancing cancer or treatment. Whether stages of quite different can cens can be grouped together and are comparable needs further investigation. Despite these problems, we felt that the system of classification used in this study did reflect the development of the disease and that as a group each suc ceeding stage represented tumor progression. The relation ship between staging and treatment supported this argu ment. Since patients who were cured or clinically tumor free were excluded from the study, most errors in staging tended to underestimate tumor involvement. The strongest depression in reactivity was observed with Stage IV patients where such errors were least serious.
A cell in the circulation of patients and healthy individuals that kills target cells rather nonselectively has been de scnibed recently (4, ii, 17, 21) . A homologous reaction has also been detected in mice and is mediated by a similar type of cell (8, 14) . To differentiate this reaction in man and mouse from immune T-ceIl-mediated cytotoxicity, it was called natural cytatoxicity (8, 9, 14, 15) . The specificity of natural cytotoxicity in mice has been reported to be against viral-related antigens (9, 12, 15) . Whether natural cytotoxic ity in man is also related to viruses or to other factors needs to be demonstrated.
Natural cytatoxicity in the direct cell-mediated cytotoxic test may be divided into selective and nonselective compo nents (26) . In testing patients and controls at random on different cultured target cells, most of the cytotoxicity ap pears to be nonsebective. Thus, when a decline in cytotoxic ity against most target cells is observed in patients with progressing cancer regardless of its type, it is more proba ble that the weakening is an effect on nonselective or natu ral cytotoxicity than on specific immune cytataxicity.
The decline in reactivity in later stages of cancer may also be explained in different ways. If some patients are treated with immunosuppressive drugs during their chemothera peutic regimen, patients as a group may be weaker reactors than healthy individuals. With few exceptions, we observed that patients undergoing chemotherapy were generally less reactive. Exclusion of patients undergoing chemotherapy, however, still revealed that cytotoxic activity of lymphocytes from patients in later stages was less than the average reactivity of persons without cancer and weaker than that of most other patients. Also if specific immune reactivity is detected only during the early stages and combines with natural reactivity observed through all stages, a declining total reactivity might also be expected . Pursuing this ap proach, however, the strongest reactivity by healthy laboma tory controls would suggest the greatest specific reactivity for this group. Studies on the strong reactivity by healthy individuals has, however, been shown to be primarily the result of N-cell activity (17) , the effector in natural cytotoxic ity.
The declining cytatoxicity appears to be closely associ ated with tumor involvement and has important implications in cancer induction and metastasis. If a robe either in sun veillance and resistance to tumor induction or in control of metastasis is postulated for N-cells, depressed reactivity would explain the progression and spread of the tumor. On the other hand, several studies have also reported nonne sponsiveness or an inability to respond or to react in the presence of the tumor (2, 5, 30) . Thus, it is essential to distinguish whether the weaker reactivity allows tumor oc cumrence and invasion or the presence of the tumor results in weaker reactivity. If the rather nonselective cytotoxicity by N-cells is really the human counterpart of natural cyto toxicity in mice, the first of these alternatives receives sup port. Kiessling et a!. (15) have shown a relationship between natural cytotoxicity and resistance to YAC Maloney virus induced leukemia cells in a semisyngeneic system (16) . Moreover, nude mice with stronger than normal natural cytotoxicity (8) are as resistant as or more resistant to the induction of tumors (24, 25) . Whether human N-cells serve a similar role needs to be investigated.
